Gilead Sciences Stock: Analyst Estimates & Ratings

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States and internationally. The company has a market cap of $211.2 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.

GILD stock has rallied the broader market over the past year, surging 42.2% compared to the S&P 500 Index’s ($SPX) 10.3% surge. Moreover, in 2026, the stock has risen by nearly 38.8%, outperforming the SPX’s 10.2% rise.      

Focusing on its industry benchmark, the State Street Healthcare Select Sector SPDR ETF (XLV) has grown 27.5% over the past year, underperforming the stock. In 2026, XLV has grown 19% and has also lagged behind the stock.

On Oct. 29, GILD stock rose 4% following the release of its better-than-expected Q3 2026 earnings. The company’s revenue for the quarter amounted to $8.3 billion, topping the Street’s estimates. Moreover, its adjusted EPS came in at $2.55, also surpassing the consensus estimates. Gilead lifted its revenue guidance for the full year to $31.15 billion at the midpoint from $30.25 billion, marking a 3% increase. 

For the current year, which ends in December, analysts expect GILD’s EPS to fall 112.6% to a loss per share of $1.03 on a diluted basis. The company surpassed the consensus estimate in each of the last four quarters. 

Among the 30 analysts covering GILD stock, the consensus is a “Strong Buy.” That’s based on 21 “Strong Buy” ratings, two “Moderate Buys,” and seven “Holds.”

The configuration has remained unchanged over the past months. 

On Oct. 31, BMO Capital analyst Evan Seigerman reiterated a “Buy” rating on Gilead Sciences and set a price target of $184. 

GILD’s mean price target of $170.55 is below the current market price. Its Street-high target of $200 implies a robust 16.8% upside from current levels.

On the date of publication, Aritra Gangopadhyay did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.